Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Consensus Rating of “Hold” from Analysts

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) have earned a consensus rating of “Hold” from the eight research firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $18.71.

A number of equities analysts have recently weighed in on ATRA shares. The Goldman Sachs Group lowered their price target on Atara Biotherapeutics from $4.00 to $3.00 and set a “sell” rating for the company in a report on Tuesday, August 9th. Citigroup cut Atara Biotherapeutics from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $8.00 to $3.00 in a report on Wednesday, July 20th. StockNews.com started coverage on Atara Biotherapeutics in a report on Wednesday, October 12th. They set a “hold” rating for the company. Finally, Mizuho lowered their price target on Atara Biotherapeutics from $39.00 to $31.00 and set a “buy” rating for the company in a report on Tuesday, August 16th.

Insider Activity at Atara Biotherapeutics

In other news, CFO Utpal Koppikar sold 5,940 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $5.04, for a total value of $29,937.60. Following the completion of the transaction, the chief financial officer now owns 197,589 shares in the company, valued at approximately $995,848.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Utpal Koppikar sold 5,940 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $5.04, for a total value of $29,937.60. Following the completion of the transaction, the chief financial officer now owns 197,589 shares in the company, valued at approximately $995,848.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Pascal Touchon sold 14,806 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, August 16th. The shares were sold at an average price of $5.04, for a total value of $74,622.24. Following the completion of the transaction, the chief executive officer now owns 457,287 shares of the company’s stock, valued at approximately $2,304,726.48. The disclosure for this sale can be found here. Insiders sold 28,300 shares of company stock worth $142,556 in the last three months. 4.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ATRA. State Street Corp boosted its holdings in Atara Biotherapeutics by 45.1% in the first quarter. State Street Corp now owns 6,273,617 shares of the biotechnology company’s stock valued at $58,282,000 after purchasing an additional 1,949,418 shares in the last quarter. Wasatch Advisors Inc. raised its holdings in Atara Biotherapeutics by 88.8% during the first quarter. Wasatch Advisors Inc. now owns 3,823,588 shares of the biotechnology company’s stock worth $35,521,000 after purchasing an additional 1,798,072 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Atara Biotherapeutics by 41.9% during the first quarter. Goldman Sachs Group Inc. now owns 3,638,106 shares of the biotechnology company’s stock worth $33,798,000 after purchasing an additional 1,073,579 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Atara Biotherapeutics by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 8,189,899 shares of the biotechnology company’s stock worth $76,085,000 after purchasing an additional 772,777 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Atara Biotherapeutics during the second quarter worth approximately $4,806,000.

Atara Biotherapeutics Stock Up 24.0 %

Shares of ATRA opened at $4.81 on Friday. Atara Biotherapeutics has a 52-week low of $2.83 and a 52-week high of $18.85. The company has a market capitalization of $453.88 million, a PE ratio of -1.95 and a beta of 1.02. The stock has a fifty day simple moving average of $4.21 and a two-hundred day simple moving average of $4.96.

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) last issued its earnings results on Monday, August 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.60. Atara Biotherapeutics had a negative return on equity of 111.20% and a negative net margin of 344.87%. The business had revenue of $51.58 million during the quarter, compared to the consensus estimate of $8.84 million. During the same period last year, the company earned ($0.91) EPS. As a group, equities analysts anticipate that Atara Biotherapeutics will post -2.16 earnings per share for the current fiscal year.

About Atara Biotherapeutics

(Get Rating)

Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.

Further Reading

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.